Abstract
13 patients suspected of intra-uterine growth retardation (IUGR) were treated with a combination of heparin and dipyridamole. The effect of this anticoagulant therapy on platelet count, clot retraction, fibrinogen degradation products, antithrombin III (AT-III), plasminogen, fibrinogen and platelet aggregation induced by epinephrine, ADP, collagen and ristocetin has been examined. All parameters were measured both before and after treatment with heparin-dipyridamole. The results were compared with the results from a control group consisting of pregnant women of the same gestational age using no medication and not suspected of IUGR (n = 17). A significant decrease in the clot retraction was observed in patients with IUGR as compared to pregnant controls (p less than 0.05). A significant decrease in the AT-III level (p less than 0.01) and a significant increase (p less than 0.01) in the fibrinogen level were observed after heparin-dipyridamole treatment of patients suspected of IUGR. We conclude that the combination of a high fibrinogen and a low AT-III level will cause an increased risk for the development of thrombosis upon termination of treatment. We also observed that heparin clearance is increased during pregnancy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
